ClinicalTrials.gg
CompletedNCT04864743Updated Sep 8, 2023

A Study to Evaluate the Pharmacokinetics,Safety and Tolerability of PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection

A Phase 1 interventional study of ADVATE and FRSW117 in Severe Hemophilia A, sponsored by Jiangsu Gensciences lnc.. Completed at 4 sites in China. Open to male participants aged 12 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-09-08.

Sponsored by Jiangsu Gensciences lnc. · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
13
Allocation
Non-randomized
Ages
12 Years to 65 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 93 studies in Hemophilia A with a site in China — 28 open to participants now, 39 under way, 19 of them phase 3. Hemophilia A · China.

Enrollment
68th of 80
13 · median 54
Started
2021
with 10 others
Phase 1
13 of 93
4 open now
Registered
44th of 93
by date
Lead sponsor
5 of 93
Jiangsu Gensciences lnc.

Among the 93 studies in Hemophilia A with a site in China, this one is the 68th largest by enrollment of the 80 interventional ones that give a count, is one of 11 that started in 2021, is one of 13 in phase 1, and was the 44th registered.

Hemophilia A

845 studies on the registry are indexed under Hemophilia A; 137 are open to participants now.

Browse Hemophilia A studies →

Open to participants now

28 of the 93 studies in Hemophilia A with a site in China are open now. Recruiting first, the newest first:

23 more — sign in →

All 28 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 88 Hemophilia A studies recruiting now, 52 (59%) set no upper age limit and 31 (35%) stop at 75 or younger; 56 take children under 18; 10 take healthy volunteers.

This study: 12 Years to 65 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 93 studies in Hemophilia A with a site in China, or all of them as a file.
02

Study summary

The primary objectives of the study are to evaluate the Pharmacokinetics,Safety and tolerability of PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection (FRSW117) in patients with severe hemophilia A.

The secondary objectives are to monitor anti-durg antibodies and anti-PEG antibodies levels in patients with severe hemophilia A

03

Conditions studied

  • Severe Hemophilia A

Browse trials for

Keywords

  • severe Hemophilia A
  • PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection
  • Pharmacokinetics
  • Efficacy and tolerability
  • Phase I
04

Who can participate

Ages eligible
12 Years to 65 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with clinically confirmed hemophilia A (coagulation factor VIII \<1%) and previous medical records confirming exposure to coagulation factor VIII for ≥150 days (EDs ≥150).
  • Non-immunodeficient, with some immunity ( > 200/μL).
  • count >100×10\^9/L.
  • Normal (PT) or international normalized ratio (INR) \<1.3.
  • Negative lupus anticoagulant.
  • Fully understand, informed about this study and sign the form, voluntarily participate in the clinical study and have the ability to complete all study procedures

Exclusion criteria

Exclusion Criteria:

  • to the test substance or its (including rodent or hamster protein).
  • Pre-existing hypersensitivity or allergic reactions to FVIII or IgG2 injection therapy.
  • Positive FVIII inhibitor at screening (≥0.6 BU/mL), or previous history of FVIII inhibitor Positive history, or family history of inhibitors.
  • Patients with other coagulation disorders in addition to hemophilia A.
  • The results of vWF antigen examination lower than normal.
  • Severe anemia and need blood transfusion ( \< 60g/L).
  • Patients who have received any standard half-lives FVIII formulations (e.g., Kogenate, Kovaltry, Advate, Xyntha, etc.) or received any other half-life-extending FVIII formulations within 4 days or 5 half-lives (whichever is longer) before administration.
  • Patients who had used emecizumab within 6 months prior to administration.
  • Patients with fever, upper respiratory tract infection or allergy symptoms within the previous 2 weeks before screening.
  • Suffer from other diseases that may increase the risk of bleeding or the risk of thrombosis.
  • Severe cardiovascular and cerebrovascular diseases: such as cerebral hemorrhage, stroke, myocardial infarction, unstable angina pectoris, congestive heart failure(the current cardiac function grade III, Hypertension that cannot be controlled with drug treatment: systolic blood pressure> 160 mmHg or diastolic blood pressure> 95 mmHg.
  • of other systematic diseases: alcoholism, drug abuse, mental disorders and mental retardation.
  • Significant hepatic or renal impairment ( and AST > 2×; serum level > 3 × upper limit of normal (ULN)).
  • Abnormal kidney function: BUN > 2×ULN, Cr > 2.0mg/dL.
  • One or more clinically significant tests for Virus Surface Antigen, (HIV), Antisyphilitic spirulina (TPHA) and Virus (HCV) Antibody.
  • Patients who received any anticoagulant or antiplatelet therapy within a week prior screening or need to receive an anticoagulant or antiplatelet therapy during the period of clinical trials.
  • Systemic immunomodulators (e.g., [equivalent dose of 10 mg/ day prednisone], A-interferon, immunoglobulin, cyclophosphamide, cyclosporine, etc.) were used within 14 days prior to administration or during the study period.
  • Patients having major surgery or receiving blood or blood components transfusion within 4 weeks prior screening or having planned major surgery schedule during the study.
  • Patients who previously participated in the other clinical trials within a month prior screening.
  • Any life-threatening disease or condition which, according to the investigator's judgment, could not benefit from the trial participation.
  • Patient who is considered by the other investigators not suitable for clinical study.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
13 participants (actual)

Study arms

  • Experimental
    Arm 1-ADVATE+FRSW117(25 IU/kg)

    Subjects received two treatments: 25 IU/kg ADVATE in the first period, followed by 25 IU/kg FRSW117 in the second period, with a washout period before each treatment.

    Drug: ADVATE · Drug: FRSW117

  • Experimental
    Arm 2-ADVATE+FRSW117( 50 IU/kg)

    Subjects received two treatments: 50 IU/kg ADVATE in the first period, followed by 50 IU/kg FRSW117 in the second period, with a washout period before each treatment.

    Drug: ADVATE · Drug: FRSW117

Interventions

06

What researchers measure

Primary outcomes

  1. Cmax from time 0 to the last data point for FRSW117 Measured by One-Stage Clotting Assay.

    Maximum plasma activity during a dosing interval for participants.

    Time frame: Pre-dose to 216 hours after the end of the infusion for Arm1; Pre-dose to 288 hours after the end of the infusion for Arm2

  2. Arm1 - T½ from time 0 to the last data point for FRSW117 Measured by One-Stage Clotting Assay.

    Time required for the activity of the drug to reach half of its original value for participants.

    Time frame: Pre-dose to 216 hours after the end of the infusion for Arm1; Pre-dose to 288 hours after the end of the infusion for Arm2

  3. Arm1 - CL from time 0 to the last data point for FRSW117 Measured by One-Stage Clotting Assay.

    Rate at which the body removes the drug, measured as the volume of the plasma cleared of drug per unit time per unit weight for participants.

    Time frame: Pre-dose to 216 hours after the end of the infusion for Arm1; Pre-dose to 288 hours after the end of the infusion for Arm2

  4. Arm1 - MRT from time 0 to the last data point for FRSW117 Measured by One-Stage Clotting Assay.

    The average time that a drug molecule is present in the systemic circulation for participants.

    Time frame: Pre-dose to 216 hours after the end of the infusion for Arm1; Pre-dose to 288 hours after the end of the infusion for Arm2

  5. Arm1 - Incremental recovery from time 0 to the last data point for FRSW117 Measured by One-Stage Clotting Assay.

    The rise in FVIII activity in IU/dL per unit dose administered in IU/kg for participants.

    Time frame: Pre-dose to 216 hours after the end of the infusion forArm1; Pre-dose to 288 hours after the end of the infusion for Arm2

  6. Arm1 - Cmax from time 0 to the last data point for ADVATE Measured by One-Stage Clotting Assay.

    Maximum plasma activity during a dosing interval for participants.

    Time frame: Pre-dose to 72 hours after the end of the infusion for Arm1; Pre-dose to120 hours after the end of the infusion for Arm2

  7. Arm1 - T½ from time 0 to the last data point for ADVATE Measured by One-Stage Clotting Assay.

    Time required for the activity of the drug to reach half of its original value for participants.

    Time frame: Pre-dose to 72 hours after the end of the infusion for Arm1; Pre-dose to120 hours after the end of the infusion for Arm2

  8. Arm1 - CL from time 0 to the last data point for ADVATE Measured by One-Stage Clotting Assay.

    Rate at which the body removes the drug, measured as the volume of the plasma cleared of drug per unit time per unit weight for participants.

    Time frame: Pre-dose to 72 hours after the end of the infusion for Arm1; Pre-dose to120 hours after the end of the infusion for Arm2

  9. Arm1 - MRT from time 0 to the last data point for ADVATE Measured by One-Stage Clotting Assay.

    The average time that a drug molecule is present in the systemic circulation for participants.

    Time frame: Pre-dose to 72 hours after the end of the infusion for Arm1; Pre-dose to120 hours after the end of the infusion for Arm2

  10. Arm1 - Incremental recovery from time 0 to the last data point for ADVATE Measured by One-Stage Clotting Assay.

    The rise in FVIII activity in IU/dL per unit dose administered in IU/kg for participants.

    Time frame: Pre-dose to 72 hours after the end of the infusion for Arm1; Pre-dose to120 hours after the end of the infusion for Arm2

  11. Number of participants with treatment-emergent adverse events (TEAEs).

    Adverse events in the study were classified and evaluated according to the National Cancer Institute's Common Terminology for Adverse Events (NCI CTCAE V5.0).

    Time frame: assessed up to four weeks after FRSW117 administration.

Secondary outcomes

  1. Evaluation of the level of anti-PEG-rFⅧFc antibody production in participants

    Time frame: assessed up to four weeks after FRSW117 administration.

  2. Evaluation of the level of anti-PEG antibody production in participants

    Time frame: assessed up to four weeks after FRSW117 administration.

  3. Number of participants with inhibitor development.

    Number of participants who developed a positive FVIII inhibitor level (≥0.6 Bethesda unit \[BU\]) during the study was summarized and classified as participants developing low titer inhibitor (i.e. ≤ 5.0 BU) and participants developing high titer inhibitor (i.e. \> 5.0 BU).

    Time frame: assessed up to four weeks after FRSW117 administration.

07

Study locations

4 sites
  • Nanfang Hospital of Southern Medical University
    Guangzhou, Guangzhou 510515, China
  • People's Hospital of Zhengzhou
    Zhengzhou, Henan 450053, China
  • Jinan central hospital
    Jinan, Shandong 250013, China
  • Institute of Hematology & Blood Diseases Hospital Chinese Academy of Medical Sciences & Peking Union Medical College.
    Tianjin, Tianjin 300020, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2021 to primary completion in Oct 2021, 3 months.

Of 37 industry-sponsored phase 1 interventional studies under Hemophilia A, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 18. This study's 3 months is below that.

Counting every sponsor, half of 46 studies reached it within 13 months; a quarter within 7 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 21, 2021
First posted
Apr 29, 2021
StartActual
Jun 22, 2021
Primary completionActual
Oct 17, 2021
CompletionActual
Oct 17, 2021
Last update
Sep 8, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 8, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04864743
Lead sponsor
Jiangsu Gensciences lnc.
Responsible party
Sponsor
First posted
Apr 29, 2021
Start date
Jun 22, 2021
Primary completion
Oct 17, 2021
Completion
Oct 17, 2021
Last update
Sep 8, 2023

Study contacts

Renchi Yang, PhD
principal investigator · Institute of Hematology & Blood Diseases Hospital Chinese Academy of Medical Sciences & Peking Union Medical College.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: FRSW117

Start the discussion